What the FDA’s High-Dose Nusinersen Approval Means for Drug Development

The FDA has approved a high-dose regimen of Biogen’s nusinersen (SPINRAZA) for the treatment of spinal muscular atrophy.1 The new regimen, comprising 50 mg/5 mL loading doses and 28 mg/5 mL maintenance doses, adds a meaningful new option to a treatment landscape that has been anchored for a decade by the original 12 mg low-dose regimen. This approval offers a notable case study in lifecycle management: how a well-characterized antisense oligonucleotide therapy can be systematically optimized through dose escalation without abandoning the clinical and regulatory foundation built by its predecessor. The high-dose regimen is already approved in the European Union, Switzerland, and Japan, with US availability expected in the coming weeks.

What Did the Clinical Program Show?

The approval rests on data from the DEVOTE study, a Phase II/III randomized, controlled, dose-escalating trial that enrolled 145 participants across ages and spinal muscular atrophy types at approximately 42 sites globally.1 The study was structured across 3 parts: an open-label safety cohort, a double-blind active-control cohort comparing the high-dose regimen against a prespecified matched untreated group drawn from the earlier ENDEAR study, and an open-label cohort evaluating the transition from the 12 mg regimen to the higher doses.

The pivotal cohort within the double-blind portion enrolled 75 treatment-naïve infants with symptomatic, infantile-onset spinal muscular atrophy.1 At 6 months, those receiving the high-dose regimen showed statistically significant improvements in motor function as measured by the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders — a mean difference of 26.19 points compared to the matched sham-control group (+15.1 vs. -11.1, p<0.0001). A supportive cohort of 24 treatment-naïve patients with later-onset disease was also included, and 40 pediatric and adult participants who transitioned from the 12 mg dose were assessed in the open-label arm.

"Optimizing the dose of nusinersen builds on a therapy that we already know can change lives. The high dose regimen demonstrated meaningful clinical benefit while maintaining a well characterized safety profile," said Richard Finkel, MD, director of Center for Experimental Neurotherapeutics, St. Jude Children's Research Hospital, in a press release.1 "I believe High Dose Spinraza will play an important role in the future of SMA care."

The use of a historical matched control from ENDEAR, rather than a concurrent placebo arm, reflects the ethical and practical constraints of conducting controlled trials in a rare pediatric population where an approved therapy already exists.1 The prespecified matching methodology provides a comparator while avoiding withheld treatment in vulnerable patients, though it also introduces considerations around comparability that regulatory reviewers will have weighed carefully.

The safety profile of the high-dose regimen was generally consistent with what has been established for the 12 mg regimen over more than a decade of use.1 The most commonly reported adverse reactions occurring in at least 10% of high-dose were pneumonia, COVID-19, pneumonia aspiration, and malnutrition, all in the infantile-onset population. The COVID-19 comparison warrants context: ENDEAR, the source of the sham-control data, predates the pandemic, making that particular adverse event comparison inherently asymmetric. Clinicians and development teams interpreting the safety data should account for this when assessing the profile.

How Does the Dosing Structure Affect Manufacturing and Supply?

The shift to a two-dose, weight-tiered loading phase with two 50 mg injections administered 14 days apart, followed by 28 mg maintenance injections every 4 months introduces new formulation and supply chain variables is something that pharmaceutical manufacturers will need to account for.1 The original 12 mg regimen had a well-established production and distribution footprint across more than 71 countries. Scaling up to accommodate both legacy and high-dose demand simultaneously, while managing distinct formulations and vial configurations, represents a meaningful operational challenge.

For patients already on the low-dose regimen, the transition path requires only a single high-dose loading injection before continuing on the 4-month maintenance schedule, a design that simplifies clinical switchover but still requires manufacturing and distribution teams to plan for a period of dual-regimen demand.1

"With more than 10 years of clinical data on SPINRAZA, the development of the High Dose Regimen reflects both the strength of that foundation and our unwavering commitment to the SMA community to optimize treatment options," said Priya Singhal, MD, MPH, executive vice president and head of development, Biogen, in the press release.1 "We are grateful to the community for their support and contributions toward this milestone."

The therapy is administered intrathecally by, or under the direction of, healthcare professionals experienced in performing lumbar punctures, which places delivery constraints outside the manufacturing chain but remains relevant context for those developing training and clinical deployment strategies.1 Biogen originally licensed the global rights to develop, manufacture, and commercialize nusinersen from Ionis Pharmaceuticals.

"Nearly ten years ago, the approval of SPINRAZA marked a turning point in SMA care and changed what the community believed was possible," said Kenneth Hobby, president, Cure SMA, in the press release.1 "Biogen understands the needs of the SMA community and has remained a committed and engaged partner to advance research that can improve the daily lives of people living with SMA."

Regulatory submissions for the high-dose regimen are ongoing in additional markets.1 The DEVOTE dataset, spanning treatment-naïve infants, later-onset patients, and those transitioning from an existing approved dose, provides an unusually broad evidentiary base for a lifecycle extension program in a rare disease setting, and one that will likely serve as a reference point for similar programs in the years ahead.

What Can Developers Learn From These Accelerated Approvals?

The nusinersen high-dose approval arrives alongside another notable regulatory milestone with direct relevance to rare disease development teams.2 The FDA granted accelerated approval to Kresladi (marnetegragene autotemcel), the first gene therapy for severe leukocyte adhesion deficiency type I in pediatric patients without an available matched sibling donor for stem cell transplant. The approval relied on surrogate biomarker endpoints, neutrophil cell surface expression, rather than direct clinical outcomes, with confirmatory trials required post-marketing. Taken together, both approvals illustrate the FDA's continued willingness to apply regulatory flexibility in rare pediatric diseases, whether through historical matched controls or novel surrogate endpoints, a pattern development teams should factor into their own evidence generation strategies.

References

1. Biogen Inc. FDA approves new high-dose regimen for SPINRAZA (nusinersen) for spinal muscular atrophy. Cambridge (MA): Biogen Inc.; 2026. Available from: https://investors.biogen.com/news-releases/news-release-details/fda-approves-new-high-dose-regimen-spinrazar-nusinersen-spinal
2. US Food and Drug Administration. FDA approves first gene therapy for severe leukocyte adhesion deficiency type I. Silver Spring (MD): US Food and Drug Administration; 2026 Mar 25. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-severe-leukocyte-adhesion-deficiency-type-i